XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2019
USD ($)
Sep. 30, 2019
Dec. 31, 2021
USD ($)
segment
Dec. 31, 2020
USD ($)
Feb. 28, 2019
Finite-Lived Intangible Assets [Line Items]          
Number of operating segments | segment     2    
Website development cost $ 46,500        
Amortization and depreciation     $ 34,161 $ 62,372  
Requisite period (in years)     3 years    
Expiration period     10 years    
Stock option vesting, description     25%    
Dividend yield     0.00% 0.00%  
Expected term     4 years    
Volatility rate minimum     84.00% 77.00%  
Volatility rate maximum     87.00% 85.00%  
Risk free interest rate, minimum     0.27% 0.22%  
Risk free interest rate, maximum     1.13% 1.66%  
Foreign currency transaction gain (loss)     $ (39,361) $ (23,385)  
Income tax benefit     (864,742) (836,893)  
Interest and penalties     0 0  
Foreign currency translation loss as cumulative translation adjustment     41,942 (24,337)  
Research and development incentive receivable     $ 225,000 434,000  
Termination benefits          
Finite-Lived Intangible Assets [Line Items]          
Expiration period     3 months    
Altamont Pharmaceutical Holdings, LLC          
Finite-Lived Intangible Assets [Line Items]          
Ownership (as a percent)         5.00%
Director [Member]          
Finite-Lived Intangible Assets [Line Items]          
Requisite period (in years)     1 year    
Website development          
Finite-Lived Intangible Assets [Line Items]          
Intangible assets, estimated useful life   3 years      
Intangible, amortization expense     $ 15,500 15,500  
Intangible, accumulated amortization     $ 38,750 $ 23,250